https://doi.org/10.4081/jbr.2023.11027

Immuno-oncological treatment of non-small-cell lung cancer in advanced stage with nivolumab

Vol. 96 No. 1 (2023)
Submitted: November 21, 2022
Accepted: January 18, 2023
Published: March 2, 2023
Cancer, lung, immuno-oncology, Nivolumab
Abstract Views: 703
PDF: 122
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Fabio Venturella
Biological, Chemical, and Pharmaceutical Science and Technologies Department, University of Palermo, Palermo, Italy.
Giulia Cancellieri
https://orcid.org/0000-0002-2437-0108
Biological, Chemical, and Pharmaceutical Science and Technologies Department, University of Palermo, Palermo, Italy.
Marco Giammanco
Surgical, Oncological and Stomatological Disciplines Department, University of Palermo, Palermo, Italy.
Anna Maria Almerico
Biological, Chemical, and Pharmaceutical Science and Technologies Department, University of Palermo, Palermo, Italy.
Igor Daniele Aleo
Indipendent Researcher, Palermo, Italy.
Anastasia Valentina Liga
Biological, Chemical, and Pharmaceutical Science and Technologies Department, University of Palermo, Palermo, Italy.
Francesca Mortillaro
https://orcid.org/0000-0002-0374-3964
Biological, Chemical, and Pharmaceutical Science and Technologies Department, University of Palermo, Palermo, Italy.
Irene Mistretta
iremistre@gmail.com
Biological, Chemical, and Pharmaceutical Science and Technologies Department, University of Palermo, Palermo, Italy.

The field of immuno-oncology has brought about a significant paradigm shift in the therapeutic approach to cancer. The implementation of a novel therapeutic approach that seeks to stimulate the immune system's response to malignant cells has resulted in a notable alteration in the clinical trajectory of advanced Non-Small Cell Lung Cancer (NSCLC) treatment. The objective of our study was to assess the therapeutic effectiveness of nivolumab as a standalone treatment for patients diagnosed with advanced stage IIIB/IV non-small cell lung cancer, namely those who had progressed beyond the second line of treatment. The findings demonstrated a progression-free survival duration of 7.35 months and a notable enhancement in patients' quality of life when compared to alternative therapeutic interventions. Furthermore, it was shown that patients who received Nivolumab did not experience any adverse reactions classified as type 3 or type 4. It is anticipated that the encouraging findings obtained thus far will contribute to a future enhancement in overall survival rates.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. DOI: https://doi.org/10.1002/ijc.29210
Passiglia F, Calandri M, Guerrera F, et al. Lung cancer in Italy. J Thorac Oncol 2019;14:2046-52. DOI: https://doi.org/10.1016/j.jtho.2019.05.019
Lindsey A. Global cancer statistics 2012. CA Cancer J Clin 2015;65:87-108. DOI: https://doi.org/10.3322/caac.21262
Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest 2017;151:193-203. DOI: https://doi.org/10.1016/j.chest.2016.10.010
Kempf E, Rousseau B, Besse B, Paz-Ares L. KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. Eur Respir Rev 2016;25:71-76. DOI: https://doi.org/10.1183/16000617.0071-2015
Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer 2016;16;4:48. DOI: https://doi.org/10.1186/s40425-016-0153-x
Reck M, Paz-Ares L. Immunologic checkpoint blockade in lung cancer. Semin Oncol 2015;42:402-17 DOI: https://doi.org/10.1053/j.seminoncol.2015.02.013
Postow MA, Callahan MK, Wolchok J D, et al. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-82. DOI: https://doi.org/10.1200/JCO.2014.59.4358
Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of Nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257-65. DOI: https://doi.org/10.1016/S1470-2045(15)70054-9
Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus Docetaxel in previously treated Non-Small-Cell Lung Cancer. J Clin Oncol 2021;39:723-33. DOI: https://doi.org/10.1200/JCO.20.01605
Murdaca G, Colombo B, Cagnati P, et al. Update upon efficacy and safety of TNF-α inhibitors, Expert Opin Drug Saf 2012;11:1-5. DOI: https://doi.org/10.1517/14740338.2012.630388

How to Cite

Venturella , F., Cancellieri, G., Giammanco, M., Almerico, A. M., Aleo, I. D., Liga, A. V., Mortillaro, F., & Mistretta, I. (2023). Immuno-oncological treatment of non-small-cell lung cancer in advanced stage with nivolumab. Journal of Biological Research - Bollettino Della Società Italiana Di Biologia Sperimentale, 96(1). https://doi.org/10.4081/jbr.2023.11027
Copyright (c) 2023 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.